FindTrial
Sign In

Comparison of Drugs, Fluvoxamine and Fluoxetine in patients with OCD in terms of efficacy and effect on clinical and biochemical parameters.

Effect of Fluvoxamine and Fluoxetine on clinical and biochemical profile of patients with Obsessive Compulsive Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048722
Enrollment
60
Registered
2023-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F42- Obsessive-compulsive disorder

Interventions

Intervention1: Fluvoxamine and Fluoxetine.: The patients will be started on 50 mg Fluvoxamine and 20 mg Fluoxetine and doses will be up titrated biweekly .Dosage of respective drugs will be kept in th

Sponsors

Government Medical College and Hospital, Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of OCD as per ICD 11 2. Drug naïve patients and patients not on medication from last 4 weeks. 3. Those consenting to participate 4. Age group 18 to 55 years 5. Any gender

Exclusion criteria

Exclusion criteria: 1. Depression and anxiety disorder of diagnosable severity . 2. Co morbid diagnosed cases of Huntington, Alzheimer, Parkinson s disease ,cancer, sepsis or history of chronic infection. 3. Patients with co morbid substance dependence (except nicotine and caffeine) . 4. Patients diagnosed with any unstable medical, surgical illness (kidney disease, liver disease, chronic heart disease , thyroid disfunction, myasthenia gravis). 5. Pregnant and lactating women. 6. Actively suicidal patients.

Design outcomes

Primary

MeasureTime frame
1.To estimate the levels of BDNF , Malondialdehyde , ESR, CRP, Procalcitonin and to corelate these with the severity of OCD. 2.To assess early response of fluvoxamine and fluoxetine in OCD and their effect on levels of BDNF, MDA, ESR, CRP, PCT and Quality of Life (QoL) at 4 weeks . Timepoint: Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks—

Secondary

MeasureTime frame
1. To compare response with Fluvoxamine and Fluoxetine in relation to clinical and biochemical profile and QoL of patients with OCD at the end of 12 weeks.Timepoint: Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks—

Countries

India

Contacts

Public ContactDr Ajeet Sidana

Government Medical College and Hospital, Chandigarh

ajeetsidana@hotmail.com9646121614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026